Health 2.0 Europe, 6-7 November 2012, Berlin
What is Health 2.0 Europe about? It's about a new generation of entrepreneurs believing they can be the change they want to see in their health systems. It's about engaging a deeper conversation and widening our perspective on today's health eco-system: it's not just about social media and communities, it's also about patient-physician communication, system reform, data, analytics, population health management, personalized medicine, sensors/devices/unplatforms, wellness... The conference is about leveraging the international Health 2... (Source: Health News from Medical News Today)

Novartis Sits In The Penalty Box
Earlier this year, I wrote a profile of Novartis and its chief executive, Joseph Jimenez, in which I detailed some of the issues hurting the company, which has traditionally been one of the stronger drug makers because of its great record of getting new medicines to market. Prospects for multiple medicines have been dashed by bad clinical trial results. Manufacturing problems hurt its generic and over-the-counter divisions, which include brands like Excedrin, TheraFlu and Triaminic. This September the U.S. patent expires on Novartis’ top seller, the blood pressure drug shy;Diovan, worth $5 billion annually, the biggest expiration the company has faced since being formed by a merger in 1996. Jimenez is unfazed. “If you look at my background in understanding the consumer,” Jimenez sa...